Lithium Ion

Lithium Ion

SCHEMBL913545

CC(C)COC[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(=O)[O-].[Li+]

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CTSK P43235 3/20 0.95
CAPN1 P07384 14/20 0.40
CTSB P07858 3/20 0.40
CAPN9 O14815 2/20 0.40
MAPK1 P28482 2/20 0.40
CTSL P07711 3/20 0.39
LMNA P02545 2/20 0.39
CTSG P08311 1/20 0.39
CTSH P09668 1/20 0.34
CTSS P25774 1/20 0.34
CTSC P53634 1/20 0.34
CYP3A4 P08684 1/20 0.34
TSHR P16473 1/20 0.34
CYP2C19 P33261 1/20 0.34
USP2 O75604 1/20 0.34
MAPT P10636 1/20 0.34
BLM P54132 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2078877 0.97 CTSK (0.95) CTSKCAPN1CTSBCAPN9MAPK1
SCHEMBL2079725 0.97 CTSK (0.95) CTSKCAPN1CTSBCAPN9MAPK1
Potassium Ion SCHEMBL913496 0.97 CTSK (0.95) CTSKCAPN1CTSBCAPN9MAPK1
SCHEMBL913738 0.97 CTSK (1.00) CTSKCAPN1CTSBCAPN9MAPK1
SCHEMBL7206790 0.86 CTSK (0.76) CTSKCAPN1CTSBCAPN9MAPK1
SCHEMBL6735420 0.86 CTSK (0.76) CTSKCAPN1CTSBCAPN9MAPK1
SCHEMBL913603 0.86 CTSK (0.76) CTSKCAPN1CTSBCAPN9MAPK1
SCHEMBL913547 0.85 CTSK (0.74) CTSKCAPN1CTSBCAPN9MAPK1
SCHEMBL2730672 0.85 CTSK (0.74) CTSKCAPN1CTSBCAPN9MAPK1
SCHEMBL14345721 0.82 CTSK (0.69) CTSKCAPN1CTSBCAPN9MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163942-B2 Salt of (2S, 3S)-3-[[(1S)-1-isobutoxymethyl-3-methylbutyl]carbamoyl]oxirane-2-carboxylic acid VELCURA THERAPEUTICS, INC. (US) 2012-04-24 US disclosed
US-20110003993-A1 SALT OF (2S, 3S) -3- [ [ (1S) -1- ISOBUTOXYMETHYL-3-METHYLBUTYL] CARBAMYL] OXIRANE-2-CARBOXYLIC ACID NIPPON CHEMIPHAR CO., LTD. (JP) 2011-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003993-A1 SALT OF (2S, 3S) -3- [ [ (1S) -1- ISOBUTOXYMETHYL-3-METHYLBUTYL] CARBAMYL] OXIRANE-2-CARBOXYLIC ACID SLC7A1, CACNA1S, SLC7A5 CTSK 823/4885CAPN1 663/4885CTSB 814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.